Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
- PMID: 28643781
- PMCID: PMC5490007
- DOI: 10.1038/ncomms15936
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
Abstract
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the largest sequencing study of osteosarcoma to date, comprising 112 childhood and adult tumours encompassing all major histological subtypes. A key finding of our study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/112 (7%) of cases. We validate this observation using fluorescence in situ hybridization (FISH) in an additional 87 osteosarcomas, with IGF1 receptor (IGF1R) amplification observed in 14% of tumours. These findings may inform patient selection in future trials of IGF1R inhibitors in osteosarcoma. Analysing patterns of mutation, we identify distinct rearrangement profiles including a process characterized by chromothripsis and amplification. This process operates recurrently at discrete genomic regions and generates driver mutations. It may represent an age-independent mutational mechanism that contributes to the development of osteosarcoma in children and adults alike.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
Comment in
-
Bone cancer: Is the osteosarcoma genome targetable?Nat Rev Endocrinol. 2017 Sep;13(9):506-508. doi: 10.1038/nrendo.2017.101. Epub 2017 Aug 4. Nat Rev Endocrinol. 2017. PMID: 28776583 No abstract available.
References
-
- Luetke A., Meyers P. A., Lewis I. & Juergens H. Osteosarcoma treatment-where do we stand? A state of the art review. Cancer. Treat. Rev. 40, 523–532 (2014). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
